Retension Pharmaceuticals closes $15 million Series B financing to advance RTN-001 for uncontrolled hypertension. The funding supports Phase 2b trials and a new patent issuance.
Retension Pharmaceuticals, focused on hypertension therapies, successfully closed its $15 million Series B financing. This funding will aid in advancing the clinical development of RTN-001 for patients with uncontrolled and resistant hypertension. Alongside this, a US patent for RTN-001 has been issued, extending protection through at least 2044. Dr
Who to call at Retension Pharmaceuticals, and when
A new round usually means Retension Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Retension Pharmaceuticals raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Retension Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Retension Pharmaceuticals. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Retension Pharmaceuticals
Location
Mclean, Virginia, United States
About
Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension. RTN-001 is a second generation PDE5i that preferentially distributes to cardiovascular tissues, where it acts to mediate a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Retension Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
McleanBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma